The relationship between the Tirzepatida, and kidneys, have drawn attention because of type-2 diabetes, obesity, high blood pressure, and cardiovascular disease are two of the main factors that increase the risk of chronic kidney disease.
In addition to lowering blood glucose, and body weight, studies Tirzepatida found favorable changes in markers linked to the renal functionhow albuminúria, and glomerular filtration rate estimated to be.
The most recent data reinforce this concern. In an exploratory analysis of pre-specified SURPASS-CVOT), published in 2026, for people with type 2 diabetes and atherosclerotic cardiovascular disease are treated with Tirzepatida had fewer events in patients than for those who received dulaglutida.
These results are promising, but need to be interpreted with caution. The Tirzepatida should not be presented as a medicine specifically approved to treat chronic kidney disease. In addition, gastrointestinal side effects such as vomiting and diarrhea can lead to dehydration, and in some cases, temporarily impair the renal function.
In this article, you are going to understand what the studies are showing the significance of the egf-r, and albuminúria, and what precautions need attention during the treatment period.
- Important: this content is purely informative and does not replace evaluation by a doctor. People with kidney disease, diabetes, high blood pressure, or the use of multiple medications, need for follow-up have been added.
Why are the kidneys so important to the health of metabolism?
The kidneys filter the blood to remove wastes, and help you to control the balance of fluids, electrolytes, and acid-base of the body.
They are also involved in the regulation of blood pressure, the production of certain hormones, the balance of the minerals.
When the renal function it begins to decrease, this change may evolve in such a way that, silent, for a long time.
For this reason, people with type 2 diabetes, high blood pressure, obesity, or heart disease usually you need to pay special attention to the health of the kidneys.
Diabetes and high blood pressure are among the most important causes of chronic kidney disease.
As the function of the kidneys is measured?
In clinical practice, one of the main markers of the glomerular filtration rate, estimated-known by the acronym s or the first time since the game is estimated.
It is calculated on the basis of blood tests, and other information to assess how well the kidneys are able to filter out.
Creatinine is a marker used for this calculation.
In some situations, it can also be used as a cystatin Cthat is less of a role in the changes in muscle mass.
This is particularly useful in the study of the large, weight-loss, as changes in body composition can change in creatinine, but not necessarily to represent a decrease in the real renal function.
What is the albuminúria?
Albuminúria means the presence of increased protein in the urine.
Albumin is a protein that is normally stays mainly in the blood. When the filters in the kidneys are injured, and a larger amount you can pass on to the urine.
An examination of widely used it is the ratio of albumin-creatinine urine, is known as the UACR.
The values are persistently elevated, may indicate an injury to the kidney and is associated with increased risk of cardiovascular disease.
For this reason, a study of the kidney does not have to show only the changes in creatinine. To reduce albuminúria can also make a change that is clinically significant.
The one who will SURPASS it 4 show?
The SURPASS-4 was evaluated for people with type 2 diabetes and high cardiovascular risk.
In a post-hoc from the results of kidney disease, the participants dealt with the Tirzepatida was down more slowly in the eGFR over time in comparison with those treated with insulin glargina.
The average annual rate of reduction of approximately At 1.4 mL/min/1,73 m2) in the group of Tirzepatida and At 3.6 mL/min/1,73 m2) in the group of insulin-glargina.
Also, there has been a favorable difference in the albuminúria.
As a UACR increased in the group of insulin-glargina, it has remained stable or showed a small decrease among participants who received the Tirzepatida.
The outcome of the kidney also occurred less frequently in the group treated with Tirzepatida. The hazard ratio was 0,58 in comparison to the insulin that is glargina.
This set of results, we raised the hypothesis that the drug could provide a benefit beyond the control of the glucose and the weight.
The meaning of the outcome of the kidney composed of?
Clinical trials are often grouped together for different events in a single picture.
The SURPASS-4, and the outcome of interest included events such as:
- drop by at least 40% of the egf-r;
- kidney disease-stage terminal;
- death from renal failure;
- the development of the macroalbuminúria.
Of the participants, and are treated with Tirzepatida had a lower occurrence of such events, in comparison with that of the insulin-glargina.
It is important, however, to remember that this was a post-hoc study, the main objective was not to test, specifically the protection of the kidney.
So it does make a difference in interpreting the strength of the evidence to support it.
The study SURMOUNT shown on the kidneys?
The study SURMOUNT have been developed primarily to assess weight control in people with obesity or overweight.
Even so, the researchers analyzed a later date markers are related to the renal function.
A publication by the year 2025, we evaluated the data of the SURMOUNT-1, and SURMOUNT-2) and found a reduction in the albuminúria among the participants, and are treated with Tirzepatida.
The reduction was particularly pronounced among people who have had UACR is high at the beginning of the study.
Among the participants with UACR the home is equal to or more than 30 mg/g, and the differences are marked by the placebo, they came about -42,3% in the SURMOUNT-1 and -55,2% in the SURMOUNT-2.
At the SURMOUNT-1), the report found favourable results from the s, when it was estimated with cystatin C.
In general, the researchers concluded that the treatment was associated with a reduction in the albuminúria with no signs of deterioration of the filtration of the kidney, in the populations studied.
Weight loss, explains part of the effect?
Most likely, yes.
Obesity may increase the pressure within the renal tubules and is associated with high blood pressure, insulin resistance, inflammation, and other factors that put a strain on the kidneys.
To reduce weight, blood pressure, and metabolic disorders, part of the charge may be reduced.
In a combined analysis of the studies on SURPASS of-1 to-SURPASS-5 has suggested that approximately one-half of the reduction in the albuminúria seen Tirzepatida could be related to weight loss.
This does not mean that the entire effect can be explained by weight loss.
The mechanisms related to the control of blood glucose levels, blood pressure, and signs of receptors and GIP, and GLP-1 have also been studied.
The one that will SURPASS-CVOT shown in 2026?
In 2026, an exploratory analysis of pre-specified SURPASS-CVOT brought in still more recent years.
The main study involved more than The 13-thousand people with type 2 diabetes and atherosclerotic cardiovascular disease.
In the analysis, the kidney, and the risk of the outcome of the composite was approximately 23% smaller with the Tirzepatida with dulaglutida.
The event took place in some of the 6.0% of the participants treated with Tirzepatida and 7.6% of those treated with dulaglutida.
The results seem to be explained by a lower occurrence of new macroalbuminúria persisted among participants in the lowest risk to the kidney and a decrease more slowly in the s among those with kidney disease in high-risk areas.
These results strengthen the hypothesis that the benefit of the renal function.
But it is still important to use the right word: it's an analysis of the kidney of the SURPASS-CVOT, and it's not a test that is developed solely to demonstrate that the Tirzepatida deals with chronic kidney disease.
Tirzepatida it protects their kidneys?
All the studies point to effects in patients with favorable, mostly a reduction of the albuminúria, and the lower the speed of the fall of the egf receptor in some people.
Still, the claim is simply that the Tirzepatida “protect my kidneys” can hide significant limitations.
The larger sets of data come from a study of people with type 2 diabetes, obesity, and high risk of cardiovascular disease.
In addition to this, many of the results patients have been analyses of the secondary, exploratory, post-hoc).
Therefore, the evidence is promising, but it needs to be interpreted within the context of the study.
Tirzepatida it is approved to treat chronic kidney disease?
Currently, it is not presented in such a way.
In Brazil, the Fda has approved Mounjaro to improve glycemic control in adults with type 2 diabetes mellitus, and later for the control of chronic weight in adults who meet the established criteria.
The existence of favourable outcomes to the renal function doesn't make you automatically to the medication, in therapy, with a specific indication for chronic kidney disease.
People with kidney disease may be an indication for treatment with the evidence of their own for the protection of the kidney, depending on the cause, the stage of the disease and other medical conditions.
Those who have kidney disease, you can use the Tirzepatida?
In the presence of renal impairment does not automatically mean that a person will not be able to use Tirzepatida.
The information that a prescription in the U.S. it is not recommended to adjust the dose for the cause of the renal failurethis , even in people with kidney disease at the stage in the terminal.
Pharmacokinetic studies have not found the change to be clinically relevant, the exposure to the Tirzepatida with different degrees of renal impairment.
This does not mean that the follow-up is necessary.
People with kidney disease may be more vulnerable to the effects of dehydration, especially for abdominal pain, nausea, vomiting, or diarrhea is important.
The decision needs to be individualized by the professional in charge.
Tirzepatida it may cause harm to the kidneys?
There is an important situation in which there may be a risk of: dehydration.
Nausea, vomiting, and diarrhea are among the adverse effects, the most well-known of the medicinal product.
When these symptoms are severe or persistent, you may lose a significant amount of water and electrolytes.
The reduction of the circulating volume may decrease blood flow to the kidneys and cause acute kidney injury.
The prescribing information for the FDA to include a warning that is specific to acute kidney injury is related to the depletion of the volume and offer recommendations on how to monitor the renal function when the adverse effects they can cause dehydration, especially at the beginning, and the increase of the dose.
Acute kidney injury is the same as chronic kidney disease?
No.
Chronic kidney disease is a persistent change in the structure or function of the kidneys in the course of a few months.
Already, the acute kidney injury occurs in a shorter period of time, and it can be due to causes such as dehydration, severe infection, decreased increased blood pressure, and / or certain medicines.
A person can develop a temporary change in the creatinine is due to dehydration, and then present a full recovery.
On the other hand, those who already have chronic kidney disease may be more vulnerable to the acute episodes.
Because of this, the symptoms of the gastro-intestinal intense during treatment, attention should also be paid.
How dehydration affects the function of the kidneys?
Your kidneys need adequate blood flow to maintain freshness.
When there is a significant loss of fluid, and the volume of the circulating blood decreases.
The body tries to compensate for it, but, if the loss is significant, the filter can fall out.
This can lead to the elevation of the creatinine and changes in the concentration of electrolyte.
Anyone who has repeated vomiting, severe diarrhea, inability to drink fluids, or a significant reduction in the amount of urine you should seek an evaluation.
It is not recommended that you simply try to “tough it out” serious symptoms, because they started after the application.
Drink plenty of water to avoid kidney problems?
There is a number of universal-water, which guarantees that the guard.
The need for liquids, it depends on the climate, physical activity, diet, body size, medicines, and medical conditions.
In addition to this, people with certain heart disease, or kidney disease you can get the guidance to limit the net.
Therefore, the recommendation to drink as much as possible,” it can also be awkward.
The goal is to maintain a hydration pack that is compatible with the needs of the individual, and to seek guidance when there is a serious loss by vomiting or diarrhea.
Creatinine may be passed over to the body.
You can.
Creatinine is related to the metabolism of the body.
While a lot of weight, change in lean body mass can change its level.
For this reason, the researchers are also using cystatin C, in some studies, in order to estimate the renal function a marker-less dependent on muscle mass.
The SURPASS-4, the analysis of cystatin C increased the observation of a reduction in the slower of the egf-r is between the participants and are treated with Tirzepatida in comparison with that of the insulin-glargina.
This increases the confidence that the findings were not explained solely by a change in the composition of the body.
Do I need to do the examinations of the kidneys by using Tirzepatida?
Every person will need to carry out tests with a frequency of just because you started the medication.
The need to depend on the clinical history.
The evaluation may be especially relevant for people with:
- diabetes, type 2 diabetes.
- - hypertension;
- kidney disease is known;
- albuminúria;
- use of water pills (diuretics);
- of old age;
- frequent episodes of vomiting or diarrhea;
- the above changes in creatinine or eGFR.
The examination may include, creatinine, eGFR, electrolyte, and compared to albumin-creatinine in the urine, as the case may be.
The professionals who are responsible should be set to the appropriate frequency.
What it means to the foam in your urine?
The urine, with a foam-casual doesn't necessarily mean kidney disease.
The speed of the jet stream, the concentration of the urine, and other factors that may cause the foam.
When the change is not persistent, especially with the swelling, or other risk factors, may be indicated to assess the presence of protein in the urine.
The albuminúria should not be determined only by the appearance of the urine.
It is necessary in the evaluation in the laboratory.
Tirzepatida substitute for all other drugs that you will protect my kidneys?
It does not automatically.
For people with diabetes and kidney disease can all use of drugs, the evidence that is specific for reducing the progression of the disease, such as certain therapies that act on the renin-angiotensin system, and inhibitors of SGLT2, depending on the indication.
The fact that the studies have shown favorable results with Tirzepatida are not benefiting from the treatment.
In practice, the drugs may have additional functions.
Which combination is appropriate depends on the blood glucose, blood pressure, eGFR, albuminúria, cardiovascular disease, and adverse effects.
To control the pressure, it is also important for the kidneys?
A lot.
High blood pressure can cause damage gradually, the blood vessels and the renal tubules.
On the other hand, kidney disease, it can also lead to an increase in the pressure.
This relationship works in both directions.
How to study with Tirzepatida found a decrease in blood pressure during weight loss, and this effect may indirectly contribute to an environment that is more conducive to the renal function.
But of hypertension, which needs specific treatment, when there is an indicator.
The control of blood sugar levels also, it protects their kidneys?
The glucose is high throughout the year, is one of the leading causes of kidney disease associated with diabetes.
To keep your diabetes under control will help to reduce the risk of complications and microvascular.
The Tirzepatida produce significant reductions in hemoglobin glicada in people with type 2 diabetes.
This is to control the metabolic likely to take part in the results of patients observed in the study.
Still, the health of the kidney depends on much more than just blood sugar levels.
Blood pressure, cigarette smoking, albuminúria, medicine, and cardiovascular disease, are also part of the assessment.
When looking for product support?
Get advice quickly when there are problems such as:
- persistent vomiting;
- severe diarrhea;
- a failure to maintain fluid;
- a significant reduction in the urine;
- light-headed, or fainting;
- weakness, and intense;
- swelling over.
- short of breath;
- confusion.
These symptoms do not necessarily mean a complication of renal failure, but it could be justified in the assessment, especially in people with kidney disease, is known to, or use of medications that affect the pressure and the fluid.
Frequently asked questions
Tirzepatida is bad for the kidneys?
The study did not show a decrease in overall renal function. On the contrary, a different analysis found a reduction in the albuminúria, and a smaller decrease in the egf-r in specific populations.
However, the dehydration caused by vomiting, or diarrhea may lead to acute kidney injury.
Tirzepatida it can improve the function of the kidneys?
Some studies have found favorable results in the marker properties. This is not to say that all people are going to have an increase for the s or the drug is to be a therapy specifically approved for chronic kidney disease.
Those who have kidney failure, you need to reduce your dosage?
The prescribing information for the FDA does not recommend adjusting the dose based on renal impairment, including renal disease is in an advanced stage.
Do I need to measure creatinine during treatment.
It depends on the individual's risk. People with kidney disease, diabetes, high blood pressure and episodes of dehydration, you may need closer follow-up.
Tirzepatida reducing protein in the urine?
Studies have found a reduction in the albuminúria, especially in participants who had high levels.
Dehydration may increase the creatinine?
Yes. The loss of important fluids may temporarily increase the filtration of the kidney, and the increase in creatinine.
Conclusion
The evidence of Tirzepatida and renal function they are becoming more and more consistent.
The SURPASS-4, the participants, and are treated with Tirzepatida declined more slowly in the s, and the lower albuminúria in comparison with that of the insulin-glargina.
Further analysis of the studies that will SURPASS and to SURMOUNT also be found favorable results in the albuminúria.
In 2026, an analysis of the pre-specified SURPASS-CVOT, he added an important fact: people with type 2 diabetes and atherosclerotic cardiovascular disease, the risk of an outcome in renal composite fence 23% smaller with the Tirzepatida with dulaglutida.
Even so, we still need to differentiate between the scientific evidence indicating a regulatory
The Tirzepatida should not be presented as a medicine specifically approved to treat chronic kidney disease.
Also, there is an important caution in the opposite direction: the effects of the gastro-intestinal intense, it can cause dehydration and lead to acute kidney injury.
For this reason, keep track of your symptoms, to maintain adequate hydration to the needs of the individual, and to carry out tests, when indicated, is an important part of the treatment is safe and secure.
The current data suggest that the renal function you can take advantage of the metabolic changes associated with the Tirzepatida in certain populations, but it is the care of the kidney continues to demand a complete assessment of blood glucose, blood pressure, albuminúria, egf-r, and the other risk factors.
References
Heerspink HJL, et al. The Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes-in-the-SURPASS-4 trial. The Medical Journal The Lancet Diabetes & Endocrinology.
The U. S. Food and Drug Administration (FDA). Mounjaro — Prescribing-Information. A review of 2026.
Content is up-to-date in August, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida the cause of indigestion? To understand the onset of discomfort after eating
Tirzepatida gives you diarrhea? Find out why it happens and what to do
